OncoMatch/Clinical Trials/NCT06522555
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Is NCT06522555 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide and zanubrutinib, rituximab and lenalidomide for diffuse large b-cell lymphoma.
Treatment: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide · zanubrutinib, rituximab and lenalidomide — A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of Pola-ZR2 (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide) versus ZR2 (zanubrutinib, rituximab and lenalidomide) in the treatment of old patients with de novo diffuse large B-cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: anti-lymphoma drugs
Exception: except glucocorticoids
Anti-lymphoma drugs have not been used before (except glucocorticoids)
Lab requirements
Blood counts
Neutrophils<1.5×10^9/L Platelets<80×10^9/L [excluded]
Kidney function
Creatinine is 1.5 times higher than the ULN or eGFR is lower than 40ml/min/1.73m^2 (according to Cockcroft-Gault Equation or MDRD Equation) [excluded]
Liver function
ALT or AST is 2 times higher than the upper limits of normal (ULN), serum bilirubin are 1.5 times higher than the ULN [excluded]
Cardiac function
uncontrollable or significant cardiovascular diseases, including but not limited to: Left ventricular ejection fraction<50%, Cardiomyopathy (dilated, hypertrophic, restrictive), QTc prolongation with clinical significance, QTc interval>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block [excluded]
Laboratory measures meet the following criteria at screening (unless caused by lymphoma): Neutrophils<1.5×10^9/L Platelets<80×10^9/L ALT or AST is 2 times higher than the upper limits of normal (ULN), serum bilirubin are 1.5 times higher than the ULN. Creatinine is 1.5 times higher than the ULN or eGFR is lower than 40ml/min/1.73m^2 (according to Cockcroft-Gault Equation or MDRD Equation). Uncontrollable or significant cardiovascular diseases, including but not limited to: Left ventricular ejection fraction<50% Cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy QTc prolongation with clinical significance, QTc interval>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify